Streetbeat News

Analyst Ratings

ESRT

Evercore ISI Group analyst Steve Sakwa upgrades Empire State Realty Trust (NYSE:ESRT) from In-Line to Outperform and raises the price target from $7 to $8.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:41 pm

MYGN

Goldman Sachs upgraded Myriad Genetics from Sell to Buy and raised its price target from $18 to $25, causing the stock to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:41 pm

PERI

Perion Network has responded to Spruce Point Capital Management's short report, stating that the company makes all required disclosures and takes all compliance measures. Perion remains focused on delivering value to clients and shareholders.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:39 pm

UPST

Compass Point analyst Giuliano Bologna maintains a Sell rating on Upstart Holdings (NASDAQ:UPST) and raises the price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:36 pm

AVGO

A whale has taken a bearish stance on Broadcom (NASDAQ:AVGO), with 68% of detected unusual options trades being bearish. Whales have been targeting a price range of $310 to $740 for Broadcom over the last 3 months. B of A Securities maintains a Buy rating with an $800 price target.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 3:32 pm

HD

A whale investor has taken a bullish stance on Home Depot (NYSE: HD), with 52% of detected trades showing bullish expectations and 47% bearish. Whales have been targeting a price range of $210 to $320 for Home Depot over the last 3 months. The stock is currently up 2.06% at $296.65, with RSI indicators suggesting it may be approaching overbought.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 3:31 pm

WPM

Wheaton Precious Metals' shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform.

Portfolio Pulse from Bill Haddad

May 23, 2023 | 3:29 pm

QTRX

Goldman Sachs upgraded Quanterix stock from Neutral to Buy and raised its price target from $13 to $27, resulting in the stock trading higher.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:24 pm

BALY

Jefferies analyst David Katz maintains a Hold rating on Ballys (NYSE:BALY) and lowers the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:20 pm

RAIN

Rain Oncology's Phase 3 MANTRA study of milademetan in dedifferentiated liposarcoma (DDLPS) failed to show statistically significant results, leading to a halt in studies for its lead candidate. Analysts have reevaluated their views on the company, with several downgrading their ratings and price targets.

Portfolio Pulse from Priya Nigam

May 23, 2023 | 3:19 pm